Region Norrbotten
- Address
- lock Available on a paid plan
Anesthesia and Analgesia
The research team at Region Norrbotten is dedicated to optimizing peri‑operative care by exploring new anesthesia protocols and pain‑management strategies.
- Evaluation of goal‑directed low oxygen concentration during surgery
- Reduction of postoperative nausea and vomiting with novel anti‑emetic regimens
- Safety assessment of surgery under general anesthesia in diverse patient groups
Conducted by AnOpIVA at Sunderby sjukhus, the site currently supports 23 clinical trials with 25 investigators, emphasizing improved recovery and patient comfort.
Bacterial Infections and Mycoses
Investigations focus on multidrug‑resistant urinary tract infections and respiratory bacterial diseases, aiming to identify effective oral alternatives and reduce antibiotic overuse.
- Oral step‑down therapy for ESBL‑producing Enterobacterales UTIs
- Comparison of phenoxymethylpenicillin versus no antibiotics for group A streptococcal‑negative tonsillitis
- Management of urinary tract infections caused by extended‑spectrum beta‑lactamases
The hospital’s antimicrobial stewardship program integrates these trials to improve infection outcomes while limiting resistance.
Female Urogenital Diseases and Pregnancy Complications
Studies aim to enhance maternal health by testing innovative approaches to labour and cervical disease prevention, including outpatient labour induction.
- Safety and effectiveness of outpatient induction of labour
- Impact of organised HPV vaccination and screening on cervical intraepithelial neoplasia
- Evaluation of prophylactic strategies for pregnancy‑related complications
Collaborations with the Swedish cervical screening program enable population‑level assessments of vaccine impact.
Hemic and Lymphatic Diseases
The site conducts cutting‑edge trials on blood‑forming and lymphatic cancers, targeting mantle cell lymphoma and related disorders with novel targeted agents and immunotherapies.
- Combination of rituximab and ibrutinib in mantle cell lymphoma
- Acalabrutinib monotherapy for chronic lymphocytic leukemia
- Subcutaneous daratumumab for high‑risk smoldering multiple myeloma
- Epco‑ritamab with lenalidomide and rituximab in relapsed follicular lymphoma
- Hydroxyurea addition to standard therapy for acute myeloid leukaemia
These investigations seek to improve survival and quality of life for patients with hematologic malignancies.
Neoplasms
Precision oncology drives research into solid tumors, with particular attention to non‑small cell lung cancer and colorectal cancer bearing molecular alterations.
- HER2‑mutated advanced NSCLC treated with targeted therapy
- Adjuvant aspirin in colorectal cancer with PIK3CA mutations
- Stage II‑III colon and rectal cancer trials focusing on molecular profiling
- Evaluation of stereotactic body radiotherapy combined with durvalumab in early‑stage NSCLC
By integrating genomic data, the centre aims to tailor treatments and extend progression‑free survival for cancer patients.
Nutritional and Metabolic Diseases
Research addresses metabolic risk factors, exploring therapies for lipid disorders and early diabetes, including a comparison of type 2 diabetes treatments.
- Evolocumab plus standard lipid management after acute myocardial infarction
- SGLT2‑inhibitor versus metformin in early type 2 diabetes
- Dyslipidemia control strategies in high‑risk cardiovascular patients
These trials support a comprehensive approach to cardiovascular health and metabolic disease prevention.
Respiratory Tract Diseases
The department evaluates innovative therapies for lung conditions, with a focus on advanced stereotactic body radiotherapy and supportive care during anesthesia.
- Durvalumab after SBRT for early‑stage NSCLC
- Post‑operative arterial oxygenation improvement with low‑oxygen anesthesia
- Management of severe acute tonsillitis affecting respiratory comfort
By linking oncology and respiratory medicine, the site seeks to enhance treatment outcomes for patients with lung disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 8 therapeutic areas and 15 of 80 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 76 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1Region Skane2active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Region Skane4trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Region Norrbotten
lock Showing 1 of 29 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized Controlled Trial Comparing Dapagliflozin Propanediol and Metformin in Early Stage Type 2 Diabetes for Mortality and Vascular Complications | Uppsala University | Phase III | Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 80 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ibrutinib | 4 | Unknown | 2016-07-25 | 2021-02-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.